[PRESS RELEASE] – TORONTO, Feb. 24, 2026 – Organigram Global Inc. announced the expansion of its international product portfolio, with the launch of Edison and BOXHOT medical cannabis vape and pastille products in Australia.
Australia has become one of the world’s most dynamic medical cannabis markets, with increasing approvals for access and prescribers utilizing a broader range of dosage forms. While flower remains a core category, alternatives such as vapes and pastilles are gaining importance, driven by demand for consistent dosing, ease of administration, and discreet, ready-to-use formats. These trends position Organigram, recognized for its expertise in developing high-quality, non-flower cannabis product formats anchored in need-state specific formulations, to have a central role as the market evolves.
“Australia represents an exciting international opportunity in medical cannabis, and we are entering the market at a pivotal moment with an informed strategy. The launch of Organigram brands in Australia coincides with our proposed acquisition of Sanity Group, one of Germany’s leading cannabis companies, marking a significant step in our international expansion,” said Megan McCrae, senior vice president of corporate strategy and international growth at Organigram. “Together, these strategic moves underscore Organigram’s commitment to broadening its global reach and reinforcing our reputation as a trusted supplier of medical cannabis. By integrating established brands from the Canadian market, with a diverse range of science-led innovative product formats, we are positioning Organigram to serve leading regulated medical cannabis markets globally, delivering consistent quality and reliability to patients across Australia and beyond.”
Organigram already supplies indoor‑grown flower to the Australian market through existing B2B supply relationships. With this expansion, the company is introducing 10 product SKUs in Australia across its Edison and BOXHOT brands.
Edison vapes will feature single-strain live terpenes extracted from Canada’s top-selling cultivars, with the terpenes shipped to Australia. The pastilles range will feature an array of established formulations developed with specific patient experiences in mind.
BOXHOT, on the other hand, will feature three of the top-selling botanical blends in Canada in the company’s proprietary wide-bodied 1.2-gram cartridges, offering patients more volume per product.
These formats reflect the company’s belief that future global growth in medical cannabis will be driven by ready-to-consume products and anchored in science and standards, where Organigram has built a competitive advantage through years of science-led innovation and product development.
“Australia is a rapidly evolving medical market where we see momentum in ready-to-consume formats beyond traditional flower. As patient and clinician preferences continue to move toward reliable, convenient, non-flower options that are grounded in science, data and rigorous quality standards, Organigram is well-positioned to participate in this next phase of growth,” said Borna Zlamalik, senior vice president of innovation and international R&D. “Our industry-leading focus on science and clinical validation – combined with our experience developing high-quality, non-flower products in Canada – give us a unique advantage as we introduce our established Canadian brands and product offerings to the Australian market.”
Organigram’s products will be available through its distribution partnership with Leafio, the wholesale distribution arm of Montu Australia, one of Australia’s leading medical cannabis distributors. Through this arrangement, Organigram’s medical cannabis products are expected to be available to more than 4,000 pharmacies via Leafio’s nationwide supply chain.
